Platelet activation by exposed collagen or thrombin initiates shape change, granule secretion, and integrin-mediated aggregation. Pathological amplification through positive feedback loops and impaired inhibitory signals (from prostacyclin, NO) drives arterial thrombosis in coronary and cerebrovascular disease.
From hemostasis pathophysiology, you know that platelets are anucleate cell fragments that circulate in a quiescent state and are rapidly recruited to sites of vascular injury to form a mechanical plug. From thrombosis pathophysiology, you know that pathological clot formation—thrombosis—occurs when hemostatic activation is inappropriately triggered or fails to remain localized. Platelet activation and aggregation is the cellular mechanism linking these two concepts: a detailed account of how the platelet goes from resting to activated to aggregated, and where that process goes wrong in disease.
In a healthy vessel, platelets flow freely without adhering to the endothelium because intact endothelial cells continuously secrete prostacyclin (PGI₂) and nitric oxide (NO), both of which keep platelets in their resting state by raising intracellular cyclic AMP and cyclic GMP, respectively. The signal to activate comes only when this protective endothelial layer is breached. The two primary activation triggers are collagen (exposed when subendothelial matrix is uncovered) and thrombin (generated by the coagulation cascade). Collagen binds platelet surface receptors GPVI and α₂β₁, while thrombin acts through protease-activated receptors (PAR-1 and PAR-4). Either signal initiates the same cascade: the platelet changes shape from a smooth disc to a spiky sphere with extended pseudopods (maximizing surface contact area), releases stored granule contents, and flips phosphatidylserine to its outer membrane leaflet to provide a pro-coagulant surface.
The granule secretion step is where platelet activation becomes self-amplifying. Alpha granules release fibrinogen, von Willebrand factor, and P-selectin. Dense granules release ADP and serotonin. ADP binds P2Y₁ and P2Y₁₂ receptors on neighboring platelets, recruiting them to the site; thromboxane A₂ (TXA₂) synthesized from arachidonic acid by activated platelets acts similarly. These positive feedback signals rapidly expand the platelet plug beyond the original activation site. The conformational change in integrin GPIIb/IIIa (αIIbβ₃) is the central molecular event in aggregation: activated GPIIb/IIIa binds fibrinogen and vWF with high affinity, cross-linking adjacent platelets into a cohesive plug. This is exactly why clopidogrel (which blocks P2Y₁₂) and aspirin (which inhibits TXA₂ synthesis by irreversibly acetylating COX-1) are effective antiplatelet drugs—they interrupt the amplification loop at two independent nodes.
Pathological arterial thrombosis occurs when this well-regulated system is triggered in the wrong context or fails to remain localized. The classic scenario is atherosclerotic plaque rupture: a lipid-rich plaque with a thin fibrous cap fractures, exposing its highly thrombogenic contents (tissue factor, collagen, oxidized lipids) to flowing blood. The local environment is ideal for massive platelet activation—there is abundant collagen, thrombin is generated immediately by tissue factor activating the extrinsic coagulation pathway, and the turbulent flow at a stenosis provides mechanical stress that activates vWF. Meanwhile, the damaged or dysfunctional endothelium surrounding the plaque has reduced prostacyclin and NO output, removing the inhibitory brake. The result is an occlusive thrombus in a coronary artery (myocardial infarction) or cerebral artery (ischemic stroke)—pathological thrombosis driven by the same machinery that normally protects the body from bleeding, now acting in a context where it causes tissue death rather than preventing it.